Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.85 |
| ▸ | PGK2 | P07205 | 1/20 | 0.85 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.77 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.77 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.70 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4804281 | 0.92 | PGK1 (0.81) | PGK1PGK2ADORA3ADORA1ADORA2B | |
| SCHEMBL6257693 | 0.88 | ADORA2A (0.71) | PGK1PGK2ADORA3ADORA1ADORA2B | |
| SCHEMBL6262513 | 0.88 | ADORA1 (0.71) | PGK1PGK2ADORA3ADORA1ADORA2B | |
| SCHEMBL5386790 | 0.88 | ADORA1 (0.71) | PGK1PGK2ADORA3ADORA1ADORA2B | |
| SCHEMBL6262523 | 0.88 | ADORA1 (0.71) | PGK1PGK2ADORA3ADORA1ADORA2B | |
| SCHEMBL6758941 | 0.87 | ADORA3 (1.00) | PGK1PGK2ADORA3ADORA1ADORA2B | |
| SCHEMBL14928752 | 0.87 | ADORA3 (1.00) | PGK1PGK2ADORA3ADORA1ADORA2B | |
| SCHEMBL4803033 | 0.87 | ADORA3 (1.00) | PGK1PGK2ADORA3ADORA1ADORA2B | |
| SCHEMBL14853634 | 0.87 | ADORA3 (1.00) | PGK1PGK2ADORA3ADORA1ADORA2B | |
| SCHEMBL18464461 | 0.87 | ADORA3 (1.00) | PGK1PGK2ADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381714-B2 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| US-20060276428-A1 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276428-A1 | A1 adenosine receptor agonists | ADORA1, ADORA2A, ADORA3 | PGK1 1806/4885PGK2 2787/4885ADORA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.